Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Human Papillomavirus Vaccines
New human papillomavirus vaccines study findings reported from National Cancer Institute
November 4th, 2008
Fresh data on human papillomavirus are presented in the report 'An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.' According to recent research published in the journal Vaccine, "This review focuses on recent publications of clinical trials of two prophylactic human papillomavirus (HPV) vaccines: Gardasil (Merck & Co., Inc., Whitehouse Station, NJ USA), a quadrivalent vaccine containing L1 virus-like particles (VLPs) of types -6, 11, 16, and 18, and Cervarix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a bivalent vaccine containing VLPs of types -16 and 18. In efficacy trials involving young women, both vaccines produced...
Source: Cancer Weekly (2008-11-04)
|
